In vivo Car-T gains traction
Clinical expansion shows regulators getting comfortable with in vivo-generated cell therapy.
Blood cancer gene therapies enter the clinic
First-in-human trial initiations feature Interius, Umoja and Vironexis.
Umoja and AbbVie chase Interius with in vivo Car-T
The companies hope to be as efficacious as ex vivo therapy, with convenience and safety advantages.
